The quest for a vaccine against HIV has been going on for about 40 years — almost as long as the virus that causes AIDS has been known to scientists and the public. There has been some progress recently with vaccines created with messenger RNA, or mRNA ...

The U.S. Food and Drug Administration announced recently that it will not review Moderna’s mRNA flu vaccine, despite late-stage trials showing it was safe and effective. The rejection has many in and outside the industry concerned about the Trump administration’s approach to vaccine development and recommendations.

As RNA therapeutics evolve far beyond their vaccine origins, a new generation of scientists and manufacturers is rethinking how to produce these complex medicines safely, efficiently, and at scale. From template design and enzymatic capping to lipid ...

Programmable nucleic acid nanoparticles boost vaccine immune responses as effectively as standard adjuvants in mice while avoiding the autoimmune risks that limit existing alternatives. (Nanowerk Spotlight) Every vaccine faces the same fundamental ...